{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:18:10Z","timestamp":1784783890834,"version":"3.55.0"},"reference-count":29,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.6844","type":"journal-article","created":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T22:18:14Z","timestamp":1472681894000},"page":"2387-2392","source":"Crossref","is-referenced-by-count":6,"title":["Twelve Weeks of Successful Smoking Cessation Therapy with Varenicline Reduces Spirometric Lung Age"],"prefix":"10.2169","volume":"55","author":[{"given":"Masahiko","family":"Iwaoka","sequence":"first","affiliation":[{"name":"Division of Cardiology, Tokyo Kita Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Tokyo Kita Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1161\/01.CIR.96.9.3243","volume":"96","author":"IS Ockene","year":"1997","unstructured":"1. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation 96: 3243-3247, 1997.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 43: 1731-1737, 2004.","DOI":"10.1016\/j.jacc.2003.12.047"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 8: 1398-1420, 1995.","DOI":"10.1183\/09031936.95.08081398"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Burrows B, Knudson RJ, Camilli AE, Lyle SK, Lebowitz MD. The "horse-racing effect" and predicting decline in forced expiratory volume in one second from screening spirometry. Am Rev Respir Dis 135: 788-793, 1987.","DOI":"10.1164\/arrd.1987.135.4.788"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tockman MS, Pearson JD, Fleg JL, et al. Rapid decline in FEV1. A new risk factor for coronary heart disease mortality. Am J Respir Crit Care Med 151: 390-398, 1995.","DOI":"10.1164\/ajrccm.151.2.7842197"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kanner RE, Connett JE, Williams DE, Buist AS. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am J Med 106: 410-416, 1999.","DOI":"10.1016\/S0002-9343(99)00056-X"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Willemse BW, Postma DS, Timens W, ten Hacken NH. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 23: 464-476, 2004.","DOI":"10.1183\/09031936.04.00012704"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Morris JF, Temple W. Spirometric "lung age" estimation for motivating smoking cessation. Prev Med 14: 655-662, 1985.","DOI":"10.1016\/0091-7435(85)90085-4"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 336: 598-600, 2008.","DOI":"10.1136\/bmj.39503.582396.25"},{"key":"10","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1186\/1471-2458-11-859","volume":"11","author":"F Martin-Lujan","year":"2011","unstructured":"10. Martin-Lujan F, Pi\u00f1ol-Moreso JL, Martin-Vergara N, et al. Effectiveness of a structured motivational intervention including smoking cessation advice and spirometry information in the primary care setting: the ESPITAP study. BMC Public Health 11: 859, 2011.","journal-title":"BMC Public Health","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2458","issn-type":"print"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kawakami N, Takatsuka N, Inaba S, Shimizu H. Development of a screening questionnaire for tobacco\/nicotine dependence according to ICD-10, DSM-III-R, and DSM-IV. Addict Behav 24: 155-166, 1999.","DOI":"10.1016\/S0306-4603(98)00127-0"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296: 56-63, 2006.","DOI":"10.1001\/jama.296.1.56"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 26: 319-338, 2005.","DOI":"10.1183\/09031936.05.00034805"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Toda R, Hoshino T, Kawayama T, et al. Validation of "lung age" measured by spirometry and handy electronic FEV1\/FEV6 meter in pulmonary diseases. Intern Med 48: 513-521, 2009.","DOI":"10.2169\/internalmedicine.48.1781"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39: 175-191, 2007.","DOI":"10.3758\/BF03193146"},{"key":"16","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(81)91338-6","volume":"2","author":"I Hjermann","year":"1981","unstructured":"16. Hjermann I, Holme I, Velve BK, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease: report from the Oslo Study Group of a randomised trial in healthy men. Lancet 2: 1303-1310, 1981.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Rose G, Hamilton PJS, Colwell L, Shipley MJ. A randomised controlled trial of anti-smoking advice: 10-year results. J Epidemiol Community Health 36: 102-108, 1982.","DOI":"10.1136\/jech.36.2.102"},{"key":"18","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.1982.03330120023025","volume":"248","author":"Multiple Risk Factor Intervention Trial Research Group null","year":"1982","unstructured":"18. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 248: 1465-1477, 1982.","journal-title":"JAMA The Journal of the American Medical Association","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"19","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) null","year":"2002","unstructured":"19. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3421, 2002.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Burchfiel CM, Marcus EB, Curb JD, et al. Effects of smoking and smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med 151: 1778-1785, 1995.","DOI":"10.1164\/ajrccm.151.6.7767520"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Townsend MC, DuChene AG, Morgan J, Browner WS. Pulmonary function in relation to cigarette smoking and smoking cessation. MRFIT Research Group. Prev Med 20: 621-637, 1991.","DOI":"10.1016\/0091-7435(91)90059-D"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Iwaoka M, Shimamura H, Tsuji T, Kugiyama K. Twelve weeks of smoking cessation therapy with varenicline increases the serum levels of apolipoprotein A-I only in the success group. J Cardiol 64: 318-323, 2014.","DOI":"10.1016\/j.jjcc.2014.02.009"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286: 64-70, 2001.","DOI":"10.1001\/jama.286.1.64"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106: 1447-1452, 2002.","DOI":"10.1161\/01.CIR.0000029743.68247.31"},{"key":"25","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1378\/chest.09-0194","volume":"136","author":"S Janda","year":"2009","unstructured":"25. Janda S, Park K, FitzGerald JM, Etminan M, Swiston J. Statins in COPD: a systematic review. Chest 136: 734-743, 2009.","journal-title":"Chest","ISSN":"https:\/\/id.crossref.org\/issn\/0012-3692","issn-type":"print"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Wang MT, Lo YW, Tsai CL, et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med 126: 598-606, 2013.","DOI":"10.1016\/j.amjmed.2013.01.036"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Sharif R, Parekh TM, Pierson KS, Kuo YF, Sharma G. Predictors of early readmission among patients 40 to 64 years of age hospitalized for chronic obstructive pulmonary disease. Ann Am Thorac Soc 11: 685-694, 2014.","DOI":"10.1513\/AnnalsATS.201310-358OC"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 370: 2201-2210, 2014.","DOI":"10.1056\/NEJMoa1403086"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Wise RA. The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression. Am J Med 119: 4-11, 2006.","DOI":"10.1016\/j.amjmed.2006.08.002"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/17\/55_55.6844\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T03:24:43Z","timestamp":1568345083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/17\/55_55.6844\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":29,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.6844","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}